All In Biotech

Drug Trial Radar · NCT00007670

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

CSP #428 - Treatment of Seizures in the Elderly Population

Last checked: Nov 19, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

720

Actual

Start

Jan 1998

Primary completion

Not stated

Study completion Mar 2003

Sponsor

Lead sponsor
US Department of Veterans AffairsFederal agency
Sponsor type
Federal agency
Collaborators
Parke-Davis; Glaxo Wellcome
First posted
Jan 4, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

New onset epilepsy in the elderly occurs in 45,000-50,000 elderly patients each year. These patients are especially vulnerable to side effects from medications because of changes caused by the aging process and the fact that these patients often have many common diseases for which they are already receiving medications for so that the likelihood of drug interactions is increased. Two new drugs, gabapentin and lamotrigine, have recently been approved by the FDA as antiepileptic drugs. These drugs have demonstrated efficacy in the treatment of partial onset seizures, the most common seizures in the elderly. These new compounds also have favorable side effect profiles and infrequent drug-drug interactions and, therefore, would be expected to be well-tolerated in the elderly.

Conditions

  • Seizures

Interventions

  • CarbamazepineDrug

  • GabapentinDrug

  • LamotrigineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham VA Medical Center

    Birmingham, Alabama

  • Carl T. Hayden VA Medical Center

    Phoenix, Arizona

  • Vamc - West Los Angeles, Los Angeles, Ca

    Los Angeles, California

  • Vamc - San Diego, San Diego, Ca

    San Diego, California

  • San Francisco VAMC

    San Francisco, California

  • Denver VA Medical Center

    Denver, Colorado

  • Vamc - Bay Pines, Fl

    Bay Pines, Florida

  • Gainesville VA Medical Center

    Gainesville, Florida

  • Miami VA Medical Center

    Miami, Florida

  • Study Chairperson

    Miami, Florida

  • Chicago VA Medical Center (West Side)

    Chicago, Illinois

  • Edward Hines Jr. VA Hospital

    Hines, Illinois

  • New Orleans VAMC

    New Orleans, Louisiana

  • Boston VA Medical Center

    Boston, Massachusetts

  • Bronx VA Medical Center

    The Bronx, New York

  • Study Chairman

    The Bronx, New York

  • Oklahoma City VA Medical Center

    Oklahoma City, Oklahoma

  • Vamc - Pittsburgh, Pittsburgh, Pa

    Pittsburgh, Pennsylvania

  • Dallas VA Medical Center

    Dallas, Texas

  • Hunter Holmes McGuire VA Medical Center

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.